Abstract
Infliximab and adalimumab are anti-tumor necrosis factor (TNF) alpha agents used for treating Crohn’s disease. Autoimmune hepatitis (AIH) is a rare complication of treatment with these drugs. We report on a case of AIH in a patient with Crohn’s disease treated with infliximab who fully recovered after drug withdrawal. More interestingly, because there were no other treatment options, the patient was then treated with adalimumab without recurrence of the liver disease and with control of the intestinal disease.
Similar content being viewed by others
References
Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53Suppl. V: v1–6
Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674–88
Germano V, Diamanti AP, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519–20
Marques M, Magro F, Carneiro F, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2008; 14: 723–5
Lichenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621–30
Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009; 28: 1001–3
Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44: 220–222
Rutgeerts P, Vermeire S, Van-Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182–97
Becker H, Willeke P, Domschke W, et al. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008; 27: 1597–8
Harada K, Akai Y, Koyama S, et al. A case of autoimmune hepatitis exacerbated by the administration of etanercept in a patient with rheumatoid arthritis. Clin Rheumatol 2008; 27: 1063–6
Acknowledgments
Professor Cravo received honoraria for the submission of the case report, which was funded by Schering-Plough/MSD Portugal. The other authors declare no potential conflicts of interest relevant to this case report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cravo, M., Silva, R. & Serrano, M. Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohn’s Disease with no Relapse After Switching to Adalimumab. BioDrugs 24 (Suppl 1), 25–27 (2010). https://doi.org/10.2165/11586210-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11586210-000000000-00000